BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Center for RNA Biomedicine - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://rna.umich.edu
X-WR-CALDESC:Events for Center for RNA Biomedicine
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Detroit
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Detroit:20221205T160000
DTEND;TZID=America/Detroit:20221205T170000
DTSTAMP:20260512T035842
CREATED:20220902T194437Z
LAST-MODIFIED:20221128T001805Z
UID:10583-1670256000-1670259600@rna.umich.edu
SUMMARY:RNA Innovation Seminar: Francesca Luca\, Wayne State University
DESCRIPTION:“Genetic\, environmental\, and developmental factors in immune cell gene expression and asthma”\nFrancesca Luca\, Ph.D.\nProfessor\nCenter for Molecular Medicine and Genetics\nWayne State University \n  \n  \nIn-person: BSRB\, ABC seminar rooms / hybrid link \nAbstract: Asthma is an immunological disorder with genetic and environmental components. In the last ten years we have been studying genetic and environmental factors that contribute to asthma severity in children living in the metropolitan Detroit area\, as part of the NHLBI funded project: Asthma in the Lives of Families Today (ALOFT). We have performed bulk and single cell RNA-sequency in this cohort and uncovered psychosocial and genetic factors associated with asthma. I will present our findings on the dynamic genetic regulation of gene expression in response to immunomodulators and during pubertal development. I will also discuss the importance of considering environmental and developmental contexts when using molecular data to study the genetic risk of asthma and other complex traits. \nKeywords: Gene expression\, gene-environment interactions\, eQTL\, asthma\, single cell genomics
URL:https://rna.umich.edu/events/francesca-luca/
LOCATION:MI
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Detroit:20221219T120000
DTEND;TZID=America/Detroit:20221219T130000
DTSTAMP:20260512T035842
CREATED:20221118T154320Z
LAST-MODIFIED:20221220T131454Z
UID:10695-1671451200-1671454800@rna.umich.edu
SUMMARY:RNA Therapeutics Seminar: Melissa Moore\, CSO\, Moderna Therapeutics\, Emerita
DESCRIPTION:“The Science Behind mRNA Medicines: COVID-19 Vaccines and Beyond”\nMelissa J. Moore\, Ph.D.\nChief Scientific Officer\, Moderna Therapeutics\, Emerita\nIn-person: BSRB\, Kahn Auditorium and hybrid. Here is the link for the seminar video. \nDr. Moore will be awarded an honorary degree at the University of Michigan Ann Arbor campus’ 2022 Winter Commencement and give this scientific talk to our RNA community. \n  \n  \nBiography: From 2016-2021\, Dr. Moore led the early-stage research teams developing Moderna’s platform technologies in mRNA design and delivery. These technologies were foundational for Moderna’s ability to rapidly create a highly effective vaccine against SARS-CoV-2. As CSO\, Emerita\, she now focuses on explaining the science behind mRNA medicines. During her 23 years as faculty member\, first at Brandeis University (1994-2007) and then at the University of Massachusetts Medical School (2007-2016)\, her research encompassed a broad array of topics related to the roles of RNA and RNA-protein (RNP) complexes in gene expression\, and touched on many human diseases including cancer\, neurodegeneration and preeclampsia. A long-time Investigator at the Howard Hughes Medical Institute (HHMI)\, Dr. Moore is an elected member of the National Academy of Sciences (2017)\, a Fellow of the American Academy of Arts and Sciences (2019)\, and recipient of the RNA Society Lifetime Achievement Award (2021).\nDr. Moore holds a B.S. in Chemistry and Biology from the College of William and Mary\, and a Ph.D. in Biological Chemistry from MIT\, where she specialized in enzymology under Prof. Christopher T. Walsh. She bean working on RNA metabolism during her postdoctoral training with Philip A. Sharp at MIT. Her passions include educating the public about the coming age of nucleic acid medicines and increasing Diversity\, Equality and Inclusion (DEI) at all levels of the biotechnology workforce.
URL:https://rna.umich.edu/events/melissa-moore-2022/
LOCATION:MI
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Detroit:20221219T160000
DTEND;TZID=America/Detroit:20221219T170000
DTSTAMP:20260512T035842
CREATED:20220902T193934Z
LAST-MODIFIED:20221219T204928Z
UID:10579-1671465600-1671469200@rna.umich.edu
SUMMARY:RNA Innovation Seminar: Hayley McLoughlin\, Neurology
DESCRIPTION:“Antisense Oligonucleotides for Ataxia”\nHayley McLoughlin\, Ph.D.\nAssistant Professor of Neurology\nAssistant Professor of Human Genetics\nUniversity of Michigan \n  \n  \nIn-person: BSRB\, ABC seminar rooms / hybrid link \nAbstract: Her talk will cover recent advances in antisense oligonucleotide (ASO) therapy with a particular emphasis towards their mechanistic and therapeutic applications in Ataxia. She will specifically discuss ASO approaches in the most common dominantly inherited ataxia\, Spinocerebellar ataxia type (SCA3). SCA3 is one of nine polyglutamine expansion diseases and is caused by a gain-of-function repeat expansion in the disease gene\, ATXN3. To date\, there is no effective treatment for this relentlessly progressive and fatal neurodegenerative disease. Throughout her postdoctoral training in Dr. Paulson’s lab and into her independent research career\, she has assessed the efficacy and tolerability of anti-ATXN3 ASO gene silencing therapy in SCA3 mouse models in collaboration with Ionis Pharmaceuticals. Published in successive cross-sectional (PMC5415970) and longitudinal studies (PMC6119475)\, they defined the first evidence of a gene therapy mitigating both pathological and behavioral disease phenotypes in the SCA3 mouse\, which overexpresses the full-length human disease gene. These anti-ATXN3 ASOs are currently begin assessed in SCA3 human subjects through a Phase 1 clinical trial driven by Biogen for pharmacokinetics and safety (ClinicalTrials.gov Identifier: NCT05160558).
URL:https://rna.umich.edu/events/hayley-mcloughlin/
LOCATION:MI
END:VEVENT
END:VCALENDAR